Verwandte Artikel zu Discovering and Developing Molecules with Optimal Drug-Like...

Discovering and Developing Molecules with Optimal Drug-Like Properties: 15 (AAPS Advances in the Pharmaceutical Sciences Series) - Softcover

 
9781493948604: Discovering and Developing Molecules with Optimal Drug-Like Properties: 15 (AAPS Advances in the Pharmaceutical Sciences Series)

Inhaltsangabe

This authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Written by leading scientists in their fields, the text consists of fourteen chapters with an underlying theme of early collaborative opportunities between pharmaceutical and discovery sciences. The book explores the practical realities of performing physical pharmaceutical and biopharmaceutical research in the context of drug discovery with short timelines and low compound availability. Chapters cover strategies and tactics to enable discovery as well as predictive approaches to establish, understand and communicate risks in early development. It also examines the detection, characterization, and assessment of risks on the solid state properties of advanced discovery and early development candidates, highlighting the link between solid state properties and critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on linking physiochemical properties of molecules to formulation selection in preclinical and clinical settings.

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

Über die Autorin bzw. den Autor

Dr. Allen C. Templeton is executive director of the Analytical Sciences organization within Merck Research Laboratories. He is responsible for the managing staff in the pursuit of scientific problem-solving for pharmaceutical product development. Before assuming his current position, Dr. Templeton held positions of increasing responsibility within Merck, including leadership roles in preformulation and formulation. Dr. Templeton earned his Ph.D. in analytical chemistry from the University of North Carolina at Chapel Hill. His research experience has been in the area of analytical and materials chemistry. He has published more than fifty articles, served as co-inventor on eleven patents and authored more than 120 presentations in the area of pharmaceutical analysis. He has organized a number of symposia and training courses on diverse topics within the field of pharmaceutical characterization. Dr. Templeton is an active member in a number of professional organizations, including the American Association of Pharmaceutical Scientists (AAPS) and the American Chemical Society (ACS). He has served in a number of roles for AAPS and is most recently the secretary/treasurer of the Physical Pharmacy and Biopharmaceutics section. He was elected to the United States Pharmacopeia (USP) expert committee on physical analysis and has worked to revise a number of USP standard chapters.  He is also currently serving on the Analytical Leadership Group for the International Consortium for Innovation & Quality in Pharmaceutical Development (IQ).  He is on the editorial advisory boards for the Journal of Pharmaceutical Sciences, American Pharmaceutical Review and Current Drug Delivery.  

 

Dr. Stephen R. Byrn is Charles B. Jordan Professor of Medicinal Chemistry in the Department of Industrial and Physical Pharmacy, Purdue University.  Dr. Byrn set in motion the development of the field ofsolid state chemistry of drugs with his books and papers on the subject. He has also taught more than 100 short courses on solid state chemistry and pharmaceutical solids and has educated more than fifty Ph.D. students and postdoctoral fellows. Dr. Byrn has had numerous grants, including one of the first thirteen from NIH Centers for AIDS Research. Dr. Byrn is cofounder of Purdue’s graduate programs in regulatory and quality compliance. He is also cofounder of the Purdue-Kilimanjaro School of Pharmacy graduate certificate program in industrial pharmacy and manufacturing in Moshi, Tanzania. Dr. Byrn has served as chair of the Pharmaceutical Sciences Advisory Committee to the FDA and chaired several USP committees. Dr. Byrn is also cofounder of SSCI, Inc. (Solid State Chemical Information), a cGMP research and information company now owned by Aptuit. Dr. Byrn is an elected Fellow of the American Association of Pharmaceutical Scientists (AAPS) and has received several awards for his research and entrepreneurial activities including the first AAPS David Grant Award for Research Achievement in Physical Pharmacy. The Journal of Pharmaceutical Sciences has a special issue dedicated to Dr. Byrn. His current research interests include strategies for accelerated drug development and the use of synchrotron X-rays for pharmaceutical research.

 

Dr. Roy J. Haskell is a Research Fellow in the Discovery Pharmaceutics group of Bristol-Myers Squibb, where he is engaged in discovery support as well as the design and characterization of novel formulations. He received a Ph.D. in Analytical Chemistry from the University of Wisconsin–Madison. He joined The Upjohn Company and worked in the area of protein biophysics. As part of Pharmacia, his focus transitioned to formulating poorly soluble molecules and characterizing the formulations by which such compounds are delivered. Dr. Haskell's research interests include design and characterization of colloidal formulations, predictive modeling of physicochemical properties, sizing submicron particles, aggregation/precipitation mechanisms, the role of solubility and supersaturation in oral absorption, and the use nanotechnology in drug discovery and development. Dr. Haskell is the author of three patents and more than 30 publications and presentations.

 

Dr. Thomas E. Prisinzano received his Ph.D. in Pharmaceutical Sciences from the School of Pharmacy, Virginia Commonwealth University, in Richmond, Virginia. He was an Intramural Research Training Award Fellow in the National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, Maryland, and is currently Professor and Chair of the Department of Medicinal Chemistry at the University of Kansas. His research focuses on the development of novel agents to treat pain, substance abuse and other CNS disorders through the identification, structure elucidation, and optimization of natural products. Dr. Prisinzano has received a number of awards including the D. John Faulkner Travel Award from the American Society of Pharmacognosy, the Jack L. Beal Award from the Journal of Natural Products, the Matt Suffness (Young Investigator) Award from the American Society of Pharmacognosy, the Joseph Cochin Young Investigator Award from the College on Problems of Drug Dependence, and the David W. Robertson Award for Excellence in Medicinal Chemistry from the American Chemical Society.

 

Von der hinteren Coverseite

This authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Written by leading scientists in their fields, the text consists of fourteen chapters with an underlying theme of early collaborative opportunities between pharmaceutical and discovery sciences. The book explores the practical realities of performing physical pharmaceutical and biopharmaceutical research in the context of drug discovery with short timelines and low compound availability. Chapters cover strategies and tactics to enable discovery as well as predictive approaches to establish, understand and communicate risks in early development. It also examines the detection, characterization and assessment of risks on the solid state properties of advanced discovery and early development candidates, highlighting the link between solid state properties and critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on linking physiochemical properties of molecules to formulation selection in preclinical and clinical settings.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

Gratis für den Versand innerhalb von/der Deutschland

Versandziele, Kosten & Dauer

Weitere beliebte Ausgaben desselben Titels

9781493913985: Discovering and Developing Molecules with Optimal Drug-Like Properties: 15 (AAPS Advances in the Pharmaceutical Sciences Series)

Vorgestellte Ausgabe

ISBN 10:  1493913980 ISBN 13:  9781493913985
Verlag: Springer, 2014
Hardcover

Suchergebnisse für Discovering and Developing Molecules with Optimal Drug-Like...

Foto des Verkäufers

Templeton, Allen C|Byrn, Stephen R.|Haskell, Roy J|Prisinzano, Thomas E.
Verlag: Springer New York, 2016
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Kartoniert / Broschiert
Print-on-Demand

Anbieter: moluna, Greven, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Kartoniert / Broschiert. Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Addresses the challenge to more efficiently select better molecules for drug developmentDiscusses how to expand the chemical space within which a pharmacological benefit can be foundExamines&nbspthe real value of discovery-oriented pharmac. Bestandsnummer des Verkäufers 447956068

Verkäufer kontaktieren

Neu kaufen

EUR 180,07
Währung umrechnen
Versand: Gratis
Innerhalb Deutschlands
Versandziele, Kosten & Dauer

Anzahl: Mehr als 20 verfügbar

In den Warenkorb

Foto des Verkäufers

Allen C Templeton
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Taschenbuch
Print-on-Demand

Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Written by leading scientists in their fields, the text consists of fourteen chapters with an underlying theme of early collaborative opportunities between pharmaceutical and discovery sciences. The book explores the practical realities of performing physical pharmaceutical and biopharmaceutical research in the context of drug discovery with short timelines and low compound availability. Chapters cover strategies and tactics to enable discovery as well as predictive approaches to establish, understand and communicate risks in early development. It also examines the detection, characterization, and assessment of risks on the solid state properties of advanced discovery and early development candidates, highlighting the link between solid state properties and critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on linking physiochemical properties of molecules to formulation selection in preclinical and clinical settings. 524 pp. Englisch. Bestandsnummer des Verkäufers 9781493948604

Verkäufer kontaktieren

Neu kaufen

EUR 213,99
Währung umrechnen
Versand: Gratis
Innerhalb Deutschlands
Versandziele, Kosten & Dauer

Anzahl: 2 verfügbar

In den Warenkorb

Foto des Verkäufers

Allen C Templeton
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Taschenbuch

Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - This authoritative volume provides a contemporary view on the latest research in molecules with optimal drug-like properties. It is a valuable source to access current best practices as well as new research techniques and strategies. Written by leading scientists in their fields, the text consists of fourteen chapters with an underlying theme of early collaborative opportunities between pharmaceutical and discovery sciences. The book explores the practical realities of performing physical pharmaceutical and biopharmaceutical research in the context of drug discovery with short timelines and low compound availability. Chapters cover strategies and tactics to enable discovery as well as predictive approaches to establish, understand and communicate risks in early development. It also examines the detection, characterization, and assessment of risks on the solid state properties of advanced discovery and early development candidates, highlighting the link between solid state propertiesand critical development parameters such as solubility and stability. Final chapters center on techniques to improve molecular solubilization and prevent precipitation, with particularly emphasis on linking physiochemical properties of molecules to formulation selection in preclinical and clinical settings. Bestandsnummer des Verkäufers 9781493948604

Verkäufer kontaktieren

Neu kaufen

EUR 217,46
Währung umrechnen
Versand: Gratis
Innerhalb Deutschlands
Versandziele, Kosten & Dauer

Anzahl: 1 verfügbar

In den Warenkorb

Beispielbild für diese ISBN

Verlag: Springer, 2016
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Softcover

Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Zustand: New. In. Bestandsnummer des Verkäufers ria9781493948604_new

Verkäufer kontaktieren

Neu kaufen

EUR 233,75
Währung umrechnen
Versand: EUR 5,91
Von Vereinigtes Königreich nach Deutschland
Versandziele, Kosten & Dauer

Anzahl: Mehr als 20 verfügbar

In den Warenkorb

Beispielbild für diese ISBN

Verlag: Springer, 2016
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Softcover

Anbieter: Lucky's Textbooks, Dallas, TX, USA

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Zustand: New. Bestandsnummer des Verkäufers ABLIING23Mar2716030186501

Verkäufer kontaktieren

Neu kaufen

EUR 210,48
Währung umrechnen
Versand: EUR 66,44
Von USA nach Deutschland
Versandziele, Kosten & Dauer

Anzahl: Mehr als 20 verfügbar

In den Warenkorb

Beispielbild für diese ISBN

Verlag: Springer, 2016
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Softcover

Anbieter: Books Puddle, New York, NY, USA

Verkäuferbewertung 4 von 5 Sternen 4 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Zustand: New. pp. 522. Bestandsnummer des Verkäufers 26378314292

Verkäufer kontaktieren

Neu kaufen

EUR 277,28
Währung umrechnen
Versand: EUR 7,97
Von USA nach Deutschland
Versandziele, Kosten & Dauer

Anzahl: 4 verfügbar

In den Warenkorb

Beispielbild für diese ISBN

Verlag: Springer, 2016
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Softcover
Print-on-Demand

Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Zustand: New. PRINT ON DEMAND pp. 522. Bestandsnummer des Verkäufers 18378314302

Verkäufer kontaktieren

Neu kaufen

EUR 294,57
Währung umrechnen
Versand: EUR 2,30
Innerhalb Deutschlands
Versandziele, Kosten & Dauer

Anzahl: 4 verfügbar

In den Warenkorb

Beispielbild für diese ISBN

Verlag: Springer, 2016
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Softcover
Print-on-Demand

Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Zustand: New. Print on Demand pp. 522. Bestandsnummer des Verkäufers 385556971

Verkäufer kontaktieren

Neu kaufen

EUR 291,45
Währung umrechnen
Versand: EUR 10,50
Von Vereinigtes Königreich nach Deutschland
Versandziele, Kosten & Dauer

Anzahl: 4 verfügbar

In den Warenkorb

Beispielbild für diese ISBN

Templeton, Allen C. (Editor)/ Byrn, Stephen R. (Editor)/ Haskell, Roy J. (Editor)/ Prisinzano, Thomas E. (Editor)
Verlag: Springer Verlag, 2016
ISBN 10: 1493948601 ISBN 13: 9781493948604
Neu Paperback

Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich

Verkäuferbewertung 5 von 5 Sternen 5 Sterne, Erfahren Sie mehr über Verkäufer-Bewertungen

Paperback. Zustand: Brand New. reprint edition. 522 pages. 9.25x6.10x1.18 inches. In Stock. Bestandsnummer des Verkäufers x-1493948601

Verkäufer kontaktieren

Neu kaufen

EUR 312,88
Währung umrechnen
Versand: EUR 11,87
Von Vereinigtes Königreich nach Deutschland
Versandziele, Kosten & Dauer

Anzahl: 2 verfügbar

In den Warenkorb